terbutaline modified-release (SKP-1052) / Vectura  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
terbutaline modified-release (SKP-1052) / Vectura
2010-022513-26: Randomised, single-blind, placebo controlled, four-period four-treatment cross-over design, proof of concept study to compare the pharmacodynamic, safety and pharmacokinetics of one single administration of SKP-1052 versus immediate-release terbutaline and placebo tablets in stable Type 1 Diabetes Mellitus Patients

Completed
2
28
Europe
SKP-1052 Modified-Release Tablets, Bricanyl, SKP-1052, Bricanyl, Bricanyl
SkyePharma AG
Type 1 Diabetes Mellitus
 
05/11

Download Options